Monitor for follow-up selling in coming weeks; if open-market dispositions continue beyond this cluster, it could signal weakening confidence. Otherwise, this appears to be a routine post-grant transaction.
QURE drugs
QURE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $10.50entry
- T+1 · 9mo ago −14.00%α −13.09% · $9.03
- T+5 · 8mo ago +71.33%α +72.54% · $17.99
- T+20 · 8mo ago +40.29%α +48.22% · $14.73
- T+60 · 6mo ago +139.52%α +130.20% · $25.15
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
uniQure's top executives, including the CEO, CFO, CMO, and Chief Legal Officer, were granted stock awards totaling over 187,000 shares (non-cash) while simultaneously selling nearly $570,000 worth of shares in the open market. The sales represent approximately 0.085% of the company's $666M market cap and appear to be routine portfolio management following a grant vesting event.
Key Financial Metrics
Key Facts
- CEO Kapusta sold $342,648 in shares; CFO Klemt sold $124,693; CMO Abi-Saab sold $16,517; Chief Legal Officer Potts sold $85,351
- All four executives received new share grants totaling 187,300 shares at $0 (non-cash awards)
- Total open-market sales: $569,209 across 57,207 shares at $9.95 per share
- Sales amount to ~0.085% of $666M market cap, below the 0.1% threshold for materiality
- Transaction pattern (sell after grant) is common in biotech and often relates to tax planning or diversification
Financial Impact
$569,209 in net insider selling, offset by non-cash grants
Risk Factors
- Perception of insider selling despite non-cash grants may weigh on sentiment
- Biotech executives often sell after vesting, pattern should be watched for escalation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-QURE-1772834899834 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers